ECSP066507A - MODULATORS OF P-SELECTINE GLICOPROTEIN BINDING PSGL- I - Google Patents

MODULATORS OF P-SELECTINE GLICOPROTEIN BINDING PSGL- I

Info

Publication number
ECSP066507A
ECSP066507A EC2006006507A ECSP066507A ECSP066507A EC SP066507 A ECSP066507 A EC SP066507A EC 2006006507 A EC2006006507 A EC 2006006507A EC SP066507 A ECSP066507 A EC SP066507A EC SP066507 A ECSP066507 A EC SP066507A
Authority
EC
Ecuador
Prior art keywords
cell
glicoprotein
selectine
modulators
cells
Prior art date
Application number
EC2006006507A
Other languages
Spanish (es)
Inventor
Rong-Hwa Lin
Chung Nan Chang
Original Assignee
Abgenomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/662,906 external-priority patent/US20040116333A1/en
Application filed by Abgenomics Corp filed Critical Abgenomics Corp
Publication of ECSP066507A publication Critical patent/ECSP066507A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Los compuestos multiméricos que se uno a P-Selectina Glicoproteina 1 (PSGL-1) sobre la superficie de las células T or natural killer (NK) cells pueden ser usadas para inducir a la célula T o la agotamiento de la céula NK y/o para inducir a la célula T o la apoptosis de la célula NK. Los compuestos multiméricos y métodos de la invención pueden ser usados para controlar las células T no deseadas o las inmuno respuestas mediadas por la célula NK en condiciones, tales como enfermedades inflamatorias, enfermedades autoinmunes, rechazo de transplantes y enfermedades alérgicas.Multimeric compounds that bind P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and / or to induce T cell or NK cell apoptosis. The multimeric compounds and methods of the invention can be used to control unwanted T cells or immune responses mediated by the NK cell under conditions, such as inflammatory diseases, autoimmune diseases, transplant rejection and allergic diseases.

EC2006006507A 2003-09-15 2006-04-13 MODULATORS OF P-SELECTINE GLICOPROTEIN BINDING PSGL- I ECSP066507A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/662,906 US20040116333A1 (en) 2001-08-03 2003-09-15 Modulators of P-selectin glycoprotein ligand 1

Publications (1)

Publication Number Publication Date
ECSP066507A true ECSP066507A (en) 2006-10-10

Family

ID=36242362

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006507A ECSP066507A (en) 2003-09-15 2006-04-13 MODULATORS OF P-SELECTINE GLICOPROTEIN BINDING PSGL- I

Country Status (16)

Country Link
EP (1) EP1663290A4 (en)
JP (1) JP5808879B2 (en)
KR (1) KR101159140B1 (en)
CN (1) CN1852730B (en)
AU (1) AU2004273807B2 (en)
BR (1) BRPI0414402A (en)
CA (1) CA2538284C (en)
EC (1) ECSP066507A (en)
IL (1) IL174172A (en)
NO (1) NO20061306L (en)
NZ (1) NZ546203A (en)
RU (1) RU2407539C2 (en)
SG (1) SG146670A1 (en)
TW (2) TW201012472A (en)
UA (1) UA91004C2 (en)
ZA (1) ZA200602151B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1751300B1 (en) * 2004-05-11 2017-11-08 AbGenomics Coöperatief U.A. T-cell death-inducing epitopes
WO2009139459A1 (en) * 2008-05-15 2009-11-19 国立大学法人 岡山大学 Method for prevention and treatment of metabolic syndrome through the inhibition of psgl-1
CN108713026B (en) * 2016-01-08 2023-01-06 美国全心医药生技股份有限公司 Tetravalent anti-PSGL-1 antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6117977A (en) * 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
ZA973051B (en) * 1996-04-24 1998-10-12 Genentech Inc Type c lectins
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies

Also Published As

Publication number Publication date
NO20061306L (en) 2006-06-14
TW201012472A (en) 2010-04-01
KR101159140B1 (en) 2012-06-22
RU2006112399A (en) 2006-08-10
JP5808879B2 (en) 2015-11-10
JP2007533618A (en) 2007-11-22
EP1663290A2 (en) 2006-06-07
CA2538284A1 (en) 2005-03-31
IL174172A0 (en) 2006-08-01
RU2407539C2 (en) 2010-12-27
TW200513262A (en) 2005-04-16
ZA200602151B (en) 2013-08-28
AU2004273807B2 (en) 2011-06-09
AU2004273807A1 (en) 2005-03-31
CA2538284C (en) 2015-10-20
IL174172A (en) 2011-12-29
CN1852730B (en) 2012-05-30
CN1852730A (en) 2006-10-25
SG146670A1 (en) 2008-10-30
EP1663290A4 (en) 2009-07-01
UA91004C2 (en) 2010-06-25
NZ546203A (en) 2009-05-31
TWI359024B (en) 2012-03-01
KR20060088104A (en) 2006-08-03
BRPI0414402A (en) 2006-11-14

Similar Documents

Publication Publication Date Title
CY1108701T1 (en) R-SELECTIN Glycoprotein 1 Regulators.
CY1119097T1 (en) ANTI-CD40 ANTI-CD40 SILVER LINE FUNCTIONS
CY1121857T1 (en) COMPOUNDS THAT EXPAND HEMAPOPOIETIC STEM CELLS
GT201500320A (en) PRODUCTION PROCESS OF BIOMASS AND METABOLITES OF MICROORGANISMS OF THE SPECIES BACILLUS SP. AND ITS COMPOSITIONS FOR BIOLOGICAL CONTROL OF PESTS
CL2019002664A1 (en) Fast and controlled administration of compositions with restored entourage effects.
MA38308A1 (en) Bispecific antigen binding molecules activating t-lymphocytes
EA201891212A1 (en) ADDRESS DISORGANIZATION OF GKGS CELL RECEPTOR
CO6501191A2 (en) CELLULAR MEDIA FOR EXPRESSION OF ADAMTS PROTEIN
PE20152005A1 (en) GLA DOMAINS AS THERAPEUTIC AGENTS
ECSP11009946A (en) Anti-CD37 antibodies
PE20110358A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF BONE DEFECTS WITH PLACENTARY CELL POPULATIONS
MA39250A1 (en) Hybrid Proteins of Interleukin-2 and Their Uses
ECSP099688A (en) MOLECULES AND METHODS TO MODULATE PRO-PROTEIN
CL2008001620A1 (en) Induction of the tolerogenic phenotype in mature dendritic cells
GT201400066A (en) APOPTOSIS INDUCTIVE AGENTS THAT CAN BE USED TO TREAT CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
IN2014DN09392A (en)
MX2010000981A (en) Antibodies to cd200 and uses thereof in inhibiting immune responses.
CL2017001903A1 (en) Novel composition for use in increasing the efficiency of hematopoietic stem cell grafting after transplantation
CO2017004735A2 (en) Molecules Having Pesticidal Utility and Related Intermediates, Compositions, and Procedures
ECSP067055A (en) T-CELL DEATH INDUCTIVE EPITHOPES
ECSP066507A (en) MODULATORS OF P-SELECTINE GLICOPROTEIN BINDING PSGL- I
WO2005027831A3 (en) Modulators of p-selectin glycoprotein ligand 1
WO2006102209A3 (en) Cd34(+) cells and their methods of use
CL2010000774A1 (en) Means for the cultivation of mammalian cells which also comprise the usual nutrients of the basal culture media for mammalian cell culture, supernatant of fraction ii + iii of human plasma according to the cohn method; preparation procedure; and its use.
PE20190966A1 (en) FACTOR VIII ADDRESSED TO RED BALLOONS AND METHOD FOR USE